

DMD # 82867

Assessment of the Biotransformation of Low Turnover Drugs in the H μ REL Human Hepatocyte Coculture Model

Richard D. Burton, Todd Hieronymus, Taysir Chamem, David Heim, Shelby Anderson,

Xiaochun Zhu, and J. Matthew Hutzler

Q² Solutions, a Quintiles Quest Joint Venture

Bioanalytical and ADME Labs

Indianapolis, IN 46241

DMD # 82867

Running Title: Human Drug Metabolism in H μ REL Hepatocyte Coculture

*Address Correspondence to:

Dr. J. Matthew Hutzler

Q² Solutions, Bioanalytical and ADME Labs

5225 Exploration Drive, Indianapolis, IN 46241

Tel: 317-857-3054

Email: matt.hutzler@Q2LabSolutions.com

Text Pages:

Tables: 1

Figures: 4

References: 23

Words in Abstract: 250

Words in Introduction: 619

Words in Results and Discussion: 1663

Non-Standard Abbreviations:

CHRM, cryopreserved hepatocyte recovery medium; DIA, data-independent acquisition; HRMS, high-resolution mass spectrometry; DDA, data-dependent acquisition;

DMD # 82867

Abstract

Metabolic profiles of four drugs possessing diverse metabolic pathways (timolol, meloxicam, linezolid, and XK469) were compared following incubations in both suspended cryopreserved human hepatocytes and the H μ REL hepatocyte coculture model. In general, minimal metabolism was observed following 4 hour incubations in both suspended hepatocytes and the H μ REL model, whereas incubations conducted up to 7 days in the H μ REL coculture model resulted in more robust metabolic turnover. In the case of timolol, in vivo human data suggests that 22% of the dose is transformed via multi-step oxidative opening of the morpholine moiety. Only the first step oxidation was detected in suspended hepatocytes, whereas the relevant downstream metabolites were produced in the H μ REL model. For meloxicam, both the hydroxymethyl and subsequent carboxylic acid were abundant following incubation in the H μ REL model, while only a trace amount of the hydroxymethyl metabolite was observed in suspension. Similar to timolol, linezolid generated substantially higher levels of morpholine ring-opened carboxylic acid metabolites in the H μ REL model. Lastly, while the major aldehyde oxidase-mediated mono-oxidative metabolite of XK469 was minimally produced in hepatocyte suspension, the H μ REL model robustly produced this metabolite, consistent with a pathway reported to account for 54% of the total urinary excretion in human. In addition, low-level taurine and glycine conjugates were identified in the H μ REL model. In summary, continuous metabolite production was observed for up to 7 days of incubation in the H μ REL model, covering cytochrome P450, aldehyde oxidase, and numerous conjugative pathways, while predominant metabolites correlated with relevant metabolites reported in human in vivo studies.

Introduction

In vitro studies directed at identifying relevant metabolites (i.e. “biotransformation” pathways) of drug candidates are a current expectation in drug discovery and development due to regulatory agency guidelines focused on metabolites in safety and drug-drug interactions (USFDA, 2016; USFDA, 2017). The objective of metabolite identification studies can vary depending on the stage of the program, ranging from early metabolic “soft-spot” assessment towards guiding medicinal chemistry strategies to improve metabolic stability, to later staged cross-species comparison of metabolic profiles to support pre-clinical toxicology species selection, and to provide an early prediction of possible in vivo human metabolism. It is also important to identify the enzyme(s) involved in generating key metabolites (reaction phenotyping). Conventional in vitro systems for evaluating metabolism include liver subcellular fractions (e.g. S9 fraction, cytosol, or microsomes) and hepatocytes (Dalvie et al., 2009; Anderson et al., 2009), each of which have advantages and disadvantages depending on the intended purpose. One disadvantage of subcellular fractions is that they only contain a subset of drug metabolizing enzymes, depending on where they are localized. With cryopreservation techniques advancing, cryopreserved hepatocytes have become more frequently utilized as they contain the full complement of oxidative, hydrolytic and conjugative enzymes, and thus provide a more comprehensive prediction of metabolism for the corresponding in vivo system (McGinnity et al., 2004; Brown et al., 2007).

In early drug discovery programs during lead optimization, one of the common parameters that drug metabolism scientists and medicinal chemists need to optimize is metabolic stability, in an effort to identify a drug candidate with likelihood of a reasonably low clearance and therapeutic dose. Metabolic soft-spot analysis in simple in vitro systems such as microsomes or hepatocytes is well suited for this objective. However, once this drug property is

DMD # 82867

optimized and metabolically stable compounds become more common, another major challenge surfaces, which is the ability to robustly characterize and differentiate low turnover (i.e. slowly metabolized) drug candidates from both a clearance rate and metabolite production standpoint. Slowly metabolized drugs require longer incubation times to enable a robust signal that can be measured with confidence (Di and Obach, 2015; Hutzler et al., 2015), which is not practical using conventional *in vitro* systems. For example, the general consensus is that metabolic enzyme activity in incubations employing human liver microsomes is only robust for roughly one hour (Foti and Fisher, 2004). In addition, hepatocytes in suspension have been reported to only maintain activity for roughly 4 hours (Di and Obach, 2015), while plating hepatocytes in a monoculture prolongs activity to approximately 24 hours, although baseline enzyme activity relative to suspension is typically less (Smith et al., 2012). In addition, 24 hour incubation times may still be insufficient for measuring turnover. As a result, novel *in vitro* methodologies, including the “relay method” using a repeat series of 4 hour incubations with suspended hepatocytes, and micropatterned coculture hepatocyte systems where incubations are conducted for up to 7 days, have been reported to perform well in the production of human relevant metabolites, both for low-turnover drugs, as well as drugs that undergo multi-step biotransformation reactions (Ballard et al., 2014; Wang et al., 2010).

The primary objective of this study was to evaluate the H μ REL human hepatocyte coculture system as a suitable *in vitro* model for generation of metabolites for low turnover drugs consistent with those observed in previously reported human clinical studies. Four commercially available drugs, timolol, meloxicam, linezolid, and XK469, were incubated for 4 hours using a conventional pooled human hepatocyte suspension, and metabolic profiles were compared to those generated in the H μ REL hepatocyte coculture model following incubation for up to 7 days.

DMD # 82867

Findings from this appraisal of the H μ REL coculture model, and the correlation with metabolic profiles in human clinical metabolism studies are reported herein.

DMD # 82867

Materials and Methods

Chemical and Biological Reagents. Timolol, meloxicam, linezolid, and XK469 were purchased from Sigma Chemicals (St. Louis, MO). Pooled cryopreserved human hepatocytes (5 donor mixed gender, Lot HSH), hepatocyte media (*InVitroGro*TM KHB for incubation) and additional cell culture reagents were obtained from BioreclamationIVT (Baltimore, MD). Cryopreserved hepatocyte recovery medium (CHRM) was obtained from APSciences, Inc. (Columbia, MD). H μ REL human hepatocyte coculture plates (24 well format) were obtained from H μ REL Corporation (North Brunswick, NJ). All other reagents and chemicals were of the highest purity available.

Hepatocyte Suspension Incubations. Pooled cryopreserved human hepatocytes were stored in liquid nitrogen until use. Immediately before experiments, vials of hepatocytes were thawed rapidly (75-90 seconds) by gently shaking in a water bath at 37 °C. The contents of each vial were diluted into 50 mL of pre-warmed (37 °C) CHRM and gently mixed before centrifugation at 100 x g for 10 minutes at room temperature. The hepatocyte pellet was re-suspended in *InVitroGro*TM KHB and the cell number and viability were determined using a Nexcelom Cellometer® K2 Image Cytometer. Hepatocyte viabilities were $\geq 93\%$. Cryopreserved hepatocyte suspensions were then diluted to 500,000 cells per incubation (0.5×10^6 cells/mL in 1 mL incubation) using *InVitroGro*TM KHB. Stock solutions of test compounds (50 mM in DMSO) were prepared and diluted to 1 mM in acetonitrile (10 μ l stock solution into 490 μ l acetonitrile). A small volume (10 μ L) of the new stock was added directly to 990 μ L of the hepatocyte suspension to initiate the incubation, giving a final concentration of 10 μ M (0.02% DMSO and 0.98% acetonitrile). A control sample (no cell control) was prepared by adding the same volume of test compound directly to *InVitroGro*TM KHB only. Verapamil (2 μ M) was

DMD # 82867

incubated as a positive control. Following 4 hours of incubation at 37 °C in an atmosphere of 5% CO₂ and 95% relative humidity while shaking at 400 rpm, samples were quenched with an equal volume of chilled acetonitrile. Samples were centrifuged at 4,000 rpm for 10 minutes and an aliquot of each supernatant was diluted 1:4 (v:v) in solvent A (0.1% formic acid in 10 mM ammonium formate) for data-independent acquisition (DIA) analyses using high-resolution mass spectrometry (HRMS). Aliquots (600 µL) of selected supernatant were dried, reconstituted in acetonitrile (30 µL) and solvent A (30 µL), and diluted 1:4 (v:v) in solvent A for data-dependent acquisition (DDA) analyses using HRMS. Control incubation samples (verapamil) were analyzed and compared to historical data to ensure metabolic competence of the hepatocytes (data not shown).

HµREL® Hepatocyte Coculture Incubations. Cryopreserved pooled human hepatocytes (5 donor mixed gender, Xenotech LLC Lot 1410235) and non-parenchymal stromal cells were cultured with HµREL® PlatinumHeps™ media by HµREL® Corporation (North Brunswick, NJ). Hepatocytes, along with non-parenchymal stromal cells were seeded into collagen coated 24-well plates at a density of 188,000 hepatocytes per well. An additional plate containing only non-parenchymal stromal cells was also prepared. After culturing for 7 days to stabilize the cultures, plates were shipped (next day) to Q² Solutions (Indianapolis, IN). Upon receipt, proprietary shipping media was replaced with HµREL® PlatinumHeps™ maintenance media. After a brief acclimation period (4 hours at 37 °C in an atmosphere of 5% CO₂ and 95% relative humidity), HµREL® PlatinumHeps™ maintenance media was replaced with 100 µL of HµREL® PlatinumHeps™ dosing media containing the appropriate test compounds (final concentration of 10 µM). Plates were incubated with gentle swirling of the plates

DMD # 82867

(approximately 120 rpm) at 37⁰C in an atmosphere of 5% CO₂ and 95% relative humidity. Following 4, 24 72, and 168 hours of incubation, supernatant from the appropriate wells was transferred to another 96-well plate. Then 100 μL of ice cold acetonitrile was added to the incubation wells, manually mixed with the pipette to capture all cellular components, transferred and combined with previously transferred incubation supernatant. Samples were centrifuged at 4,000 rpm for 10 minutes and an aliquot of each supernatant was diluted 1:4 (v:v) in solvent A (0.1% formic acid in 10 mM ammonium formate) for data-independent acquisition (DIA) analyses using high-resolution mass spectrometry (HRMS). Aliquots (600 μL) of selected supernatant were dried, reconstituted in acetonitrile (30 μL) and solvent A (30 μL), and diluted 1:4 (v:v) in solvent A for data-dependent acquisition (DDA) analyses using HRMS.

Mass Spectrometry Analysis. Metabolite profiles were generated using a high-resolution LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an electrospray ionization source and connected to a Nexera X2 liquid chromatography (LC) system (Shimadzu Corporation, Kyoto, Japan). Chromatographic separations were performed on a Supelco Ascentis Express C18 column (2.7 μm, 2.1 × 150 mm; Sigma-Aldrich, St. Louis, MO) at 25°C using a gradient elution with solvent A (0.1% formic acid in 10 mM ammonium formate) and solvent B (acetonitrile). The gradient was initiated at a 95% A/5% B ratio at a flow rate of 0.15 mL/min, held for 2 min, ramped linearly from 5% B to X% B over 40 min (where X = 20% for samples incubated with timolol, 60% for meloxicam, 25% for linezolid, and 70% for XK469), then to 95% B over the next 0.1 min, and held for 5 min. The column re-equilibration time was 13 min (total run time, 60 min). The mass spectrometer was operated in positive ion mode at a source voltage of 5 kV. N₂ sheath gas flow was set at 80 U, N₂ aux gas was set at 20

DMD # 82867

U, and capillary temperature was set at 350°C. The mass range of full-scan MS was 100 to 1000 Da and resolution was set at 30,000. MS/MS spectra for data-independent acquisition (DIA) were obtained using source-induced collision energy of 50 V for analyses of diluted supernatant. MS/MS spectra for data-dependent acquisition (DDA) were obtained using higher-energy C-trap dissociation (HCD) normalized collision energy of 50, 25, 50, and 40, for dried, reconstituted supernatant incubated with timolol, meloxicam, linezolid, and XK469, respectively.

Metabolite Identification from Suspension and H μ REL Coculture. Accurate mass MS and MS/MS data were obtained using a Thermo Fisher LTQ-Orbitrap XL coupled to a Shimadzu 10AD VP HPLC. The MS data was analyzed for predicted biotransformation pathways, as well as metabolites previously reported in human in vivo studies. Accurate mass MS/MS data were acquired using data-independent acquisition (DIA), and the MS/MS data were searched for parent drug fragment ions, as well as predicted metabolite fragment ions. Metabolite target lists were generated from the MS (predicted metabolite hits) and MS/MS (DIA – predicted metabolite fragment hits) data. Data dependent acquisition (DDA) was utilized to obtain more definitive metabolite structural information. Metabolite structures were correlated with literature data obtained from human clinical studies.

Results and Discussion

With low turnover drug molecules becoming more prevalent due to successful medicinal chemistry optimization of metabolic stability properties, the challenge of how to adequately characterize and differentiate drug candidates that are slowly metabolized has come to the forefront as one of the top issues in the drug metabolism field today (Di and Obach, 2015; Hutzler et al., 2015). This challenge has forced the drug metabolism community to investigate novel assay formats that enable longer incubation times to allow for sufficiently measurable metabolism to occur for slowly metabolized drugs (Wang et al., 2010; Ballard et al., 2014). This work from Pfizer has been recently expanded to also include an appraisal of the multispecies micropatterned coculture system using drugs known to have species-specific metabolism (Ballard et al., 2016), a critical endeavor when selecting preclinical species for in vivo pharmacology or toxicology testing. An additional in vitro hepatocyte coculture model has also become available (H μ REL[®]), with an initial appraisal of the performance of this system for predicting intrinsic clearance and metabolite identification published by two teams at AstraZeneca (Hultman et al., 2016; Bonn et al., 2016). To further investigate the performance of the H μ REL human hepatocyte coculture system, we selected four commercially available drugs (timolol, meloxicam, linezolid, and XK469) and incubated them for 4 hours using a conventional pooled human hepatocyte suspension, to compare metabolite profiles to those generated in the H μ REL hepatocyte coculture model following incubation for up to 7 days, which is an extension beyond previously published data where incubations were conducted for up to 3 days. In addition, the metabolites generated in vitro in both suspended hepatocytes and the H μ REL human hepatocyte coculture model were compared to published human in vivo metabolism data.

DMD # 82867

Timolol. Incubation of timolol in a suspension of cryopreserved pooled human hepatocytes for 4 hours, a commonly used in vitro methodology in drug metabolism labs to estimate and compare major metabolites in human and preclinical species, resulted in minimal metabolic turnover, producing only one minor mono-oxidative metabolite T5 (Figure 1A). In contrast, following incubation in the H μ REL hepatocyte coculture model for up to 7 days, more robust metabolite generation was observed (Figure 1A). In particular, by 24 hours of incubation, multiple oxidation steps on the morpholine ring resulted in formation of T3 and T4, as well as the terminal product, T2 (Figure 1A and 1B). It was also apparent that these multi-step metabolites continued to accumulate over the 7 days of incubation (Figure 1A). Both T2 and T3 metabolites of timolol have previously been reported to be the major urinary metabolites of timolol in man (Tocco et al., 1980). Thus, it appears that an in vitro system that allows for longer incubation time of timolol results in generation of multi-step metabolites that are consistent with the reported in vivo metabolism in human. Meanwhile, oxidation of the oxypropanolamine sidechain of timolol, which was reported as a minor pathway in vivo in human (Tocco et al., 1980), was not observed with either the conventional or H μ REL hepatocyte coculture incubations (Figure 1B). Interestingly, direct glucuronide conjugation (T1) was observed in vitro in the H μ REL system, and appears to represent a predominant metabolic pathway with continuous accumulation over 7 days (Figure 1A). However, this conjugative metabolite was not reported previously in vivo (Tocco et al., 1980), which may be the result of advancement of analytical techniques, or this metabolite being unstable or excreted into bile or feces and thus, not identified in early metabolite identification work. All observed metabolites, accurate mass information, and key fragment ions are summarized in Supplemental Table 1.

DMD # 82867

Meloxicam. Profiling of drug metabolites following a 4 hour incubation of meloxicam with a conventional human hepatocyte suspension revealed minimal metabolic turnover with only parent drug and 1 minor metabolite M5 being identified (Figure 2A). The metabolite M5 was formed from hydroxylation of the methyl substituent of the methylthiazole moiety. Incubation of meloxicam utilizing the H μ REL model generated a similar metabolic profile to the suspension hepatocytes following 4 hour incubation. More metabolites appeared at 24 hour and up to 7-day incubation with oxidation of the methylthiazole moiety representing the three most abundant metabolites (M4, M5, and M6). Two of these metabolites exhibited oxidation of the methyl group in the form of hydroxylation (M5) and the corresponding carboxylic acid (M4). Previously, M4 was found to be a major metabolite in human, representing approximately 60% of the dose (Schmid et al., 1995). Thus, the H μ REL model more accurately predicted the in vivo metabolism of meloxicam than incubations using suspended hepatocytes (Figure 2B). The metabolic profile for the H μ REL model at 4 hours was comparable to that observed for the conventional suspension hepatocytes, suggesting that the two hepatocytes systems had similar biological function in drug metabolism and the higher turnover observed from 24 hours to 7 days was mostly due to the longer-term viability of the hepatocytes in the H μ REL system. As M4 was the secondary metabolite of M5, its formation required a longer incubation time. Consequently, it was not observed at 4 hour incubation in both systems and first observed at 24 hour H μ REL model. Additional minor metabolites were observed resulting from hydroxylation (M3), glucuronide conjugation (M1), and oxidative cleavage (M2). All observed metabolites, accurate mass information, and key fragment ions are summarized in Supplemental Table 1.

DMD # 82867

Linezolid. Incubation of linezolid using the conventional hepatocyte approach yielded only two minor metabolites, L1 and L2, which resulted from oxidative ring-opening of the morpholine moiety. The metabolic profile was similar to that generated in the H μ REL model following incubation for 4 hours. When the incubation time was prolonged, both metabolites were consistently produced and accumulated in the H μ REL model. At day 7, the two metabolites were predominant and detected at a much higher level than those observed following a 4 hour incubation, with L1 more abundant than L2 (Figure 3A). Consistently, L1 and L2 were reported to be prominent in human following oral dose of linezolid (Slatter et al., 2001), representing 45% and 11%, respectively, of the dose recovered in excreta at steady-state. Additional metabolites L3, L4, and L5 via the opening of the morpholine ring were observed in the H μ REL model but not in suspended hepatocytes as shown in Figure 3B. These metabolites were also observed in the human in vivo study (Slatter et al., 2001). Therefore, the H μ REL model again more closely predicted the in vivo metabolism of linezolid relative to hepatocytes in suspension. Interestingly, similar metabolic profile of linezolid at day 7 was observed in another long-lived hepatocyte model, micropatterned hepatocyte coculture (Wang et al., 2010). This comparable result seems to suggest that the reason for generating more robust metabolites in the coculture models than suspension hepatocytes is driven by the longer action on the drug by the enzymes in the system. All observed metabolites, accurate mass information, and key fragment ions are summarized in Supplemental Table 1.

XK469. Incubation of XK469 in cryopreserved pooled human hepatocyte suspension for 4 hours produced only a single low abundant metabolite X6, while the H μ REL model produced robust metabolic turnover by 24 hours to a variety of metabolites covering both oxidative and

DMD # 82867

conjugative pathways, with viable metabolism observed for up to 7 days (Figure 4A and 4B). X6 was the major metabolite detected at day 3 and day 7, which was produced resulting from mono-oxidation of the quinoxaline moiety. The oxidation on this position of XK469 molecule is reported to be catalyzed by a nucleophilic mechanism via the molybdenum hydroxylase enzyme aldehyde oxidase (AO) (Anderson et al., 2005; Hutzler et al., 2012). This AO-derived metabolite was observed to be a major metabolite in human (Anderson et al., 2005), accounting for 54% of total urinary excretion. In addition, taurine (X4), glycine (X5), and glucuronide conjugates (X-Gluc) were produced following incubation of XK469 in the H μ REL model, which were all observed previously in human, albeit at low levels. One metabolite reported in human, an N-oxide, was not observed following incubations using either the conventional hepatocyte suspension or H μ REL model. Cysteine (X1 and X2) and acetylcysteine (X3) conjugates produced via the H μ REL platform were not previously reported in human. Overall, the H μ REL coculture system produced a metabolite profile that was much more complete and consistent with the human in vivo profile of XK469. All observed metabolites, accurate mass information, and key fragment ions are summarized in Supplemental Table 1.

While metabolite identification studies were only conducted with the selected test molecules in human hepatocytes using the H μ REL model, XK469 represents a good example of a drug that is slowly, but extensively metabolized by multiple pathways, including AO (Anderson et al., 2005; Hutzler et al., 2012), which demonstrates profound species differences in expression and activity (Hutzler et al., 2013). If an uncharacterized novel drug candidate with similar metabolic properties to XK469 (i.e. extremely slowly metabolized) was to be incubated in a standard 4 hour human hepatocyte suspension, what happens to be an in vivo relevant metabolic pathway may be completely missed, or under-estimated. In addition, possible species

DMD # 82867

differences in metabolism are less likely to be uncovered for slowly metabolized drugs in standard suspension incubations of limited duration (e.g. 4 hours). In the case of XK469, the AO pathway represents the predominant metabolic route, which is important to be realized prior to regulatory in vivo toxicology studies, and certainly prior to phase I human studies. SGX523 was an oncology drug candidate that was predominantly metabolized by AO to an insoluble metabolite that crystallized in the kidney and led to acute renal toxicity in human patients (Diamond et al., 2010). The AO pathway was completely missed in this example due to in vitro studies only being conducted in microsomal fractions (devoid of AO), as well as toxicology studies being conducted in rat and dog, which are poor surrogates for human AO activity. However, the same scenario could be realized for a slowly metabolized AO substrate unless incubations are conducted for a long enough period to robustly generate metabolites for a clearer picture of the possible species-specific metabolic fate of a drug candidate.

Conclusions

In our studies evaluating four low turnover drugs, the H μ REL coculture model was able to generate a more robust metabolite profile over 7 days than what was observed following incubation using conventional hepatocyte suspension. There were only one or two minor metabolites detected following suspension hepatocyte incubations with timolol, meloxicam, linezolid, and XK469 (Figures 1-4). In comparison, multiple relevant human metabolites were detected in the corresponding H μ REL incubations (Figures 1-4), which indicates that key metabolites are less likely to be missed during metabolite identification studies in a long-term coculture model such as H μ REL. For example, the human predominant in vivo metabolites including T2, T3, M4, M5, L1, L2, and X6 (AO) were all observed at an appreciable level in the H μ REL model (Table 1 and

DMD # 82867

Figures 1-4). However, T2, T3, and M4 were not detected in the 4 hour suspension hepatocytes, likely because secondary and tertiary metabolites require longer exposure of the primary metabolites in the in vitro system. Collectively, data from these studies suggest that the H μ REL model maintains metabolic activity over a diverse array of metabolic enzymes, and is a more ideal in vitro system than the conventional hepatocyte suspension in terms of in vivo metabolism prediction for low turnover compounds or compounds that undergo multi-step biotransformation.

While our studies only involved assessment of human metabolism, the H μ REL model has multiple species of pooled hepatocytes to choose from to accommodate different study designs for species comparisons. Some conveniences of this model in comparison to other in vitro methods is worth consideration. Hepatocytes used in the coculture system are cultured by H μ REL Corporation according to the client preferred plate design for 7 days (acclimation period for peak enzyme activity) prior to being shipped to the lab. Upon receipt, the incubation of test articles can be initiated in as soon as 4 hours (following media change and acclimation period), and metabolite formation can be assessed at preferred times for up to 7 days. Thus, the system is more flexible and less labor intensive than other reported methodologies such as the relay method, which requires daily hepatocyte thawing and resuspension of supernatants from the previous day. Another advantage over other coculture models is that pooled hepatocytes can be plated in the HuREL model, whereas other models such as HepatoPac require plating of individual donors (Chan et al., 2013), which will lead to increased samples for analysis if multiple individual donors need to be evaluated. Nonetheless, just like any in vitro hepatocyte model, the metabolite data produced in the H μ REL model is ultimately dependent on the enzyme activity in the hepatocyte pools selected. The next focus of studies in our lab will be to assess the suitability of the HuREL

DMD # 82867

model for enzyme phenotyping, an additional major challenge for drugs that are slowly metabolized and require longer incubation time.

DMD # 82867

Authorship Contributions

Participated in research design: Hutzler, Hieronymus, Anderson, Heim, Burton, Chamem

Conducted experiments: Chamem, Hieronymus, Heim

Contributed new reagent or analytic tools: n/a

Performed data analysis: Heim, Burton, Anderson

Wrote or contributed to the writing of the manuscript: Hutzler, Hieronymus, Anderson, Heim,
Burton, Chamem, Zhu

DMD # 82867

References

Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, and Ivy SP (2005) Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. *Cancer Chemother Pharmacol* **56**:351–357.

Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? *Chem Res Toxicol* **22**: 243-256.

Ballard TE, Orozco CC, and Obach RS (2014) Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method. *Drug Metab Dispos* **42**: 899-902.

Ballard TE, Wang S, Cox LM, Moen MA, Krzyzewski S, Ukairo O, and Obach RS (2016) Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism. *Drug Metab Dispos* **44**: 172-179.

Bonn B, Svanberg P, Janefeldt A, Hultman Ia, and Grime K (2016) Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and HepaRG. *Drug Metab Dispos* **44**: 527-533.

DMD # 82867

Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. *Drug Metab Dispos* **35**: 293-301.

Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. *Drug Metab Dispos* **41**: 2024-2032.

Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, and Smith DA (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. *Chem Res Toxicol* **22**: 357-368.

Di L and Obach RS (2015) Addressing the challenges of low clearance in drug research. *AAPS J* **17**: 352-357.

Diamond S, Boer J, Maduskuie TP, Jr., Falahatpisheh N, Li Y, and Yeleswaram S (2010) Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. *Drug Metab Dispos* **38**: 1277-1285.

Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. *Drug Metab Dispos* **32**: 295-304.

DMD # 82867

Hultman Ia, Vedin C, Abrahamsson A, Winiwarter S, and Darnell M (2016) Use of H μ REL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds. *Mol Pharm* **13**: 2796-2807.

Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. *Expert Opin Drug Metab Toxicol* **9**: 153-168.

Hutzler JM, Ring BJ, and Anderson SR (2015) Low-turnover drug molecules: A current challenge for drug metabolism scientists. *Drug Metab Dispos* **43**: 1917-1928.

Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J and Fisher MB (2012) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. *Drug Metab Dispos* **40**: 267-275.

McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. *Drug Metab Dispos* **32**: 1247-1253.

Schmid J, Busch U, Heinzl G, Bozler G, Kaschke S and Kummer M (1995) Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. *Drug Metab Dispos* **23**: 1206-1213.

DMD # 82867

Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, and Shobe EM (2001) Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. *Drug Metab Dispos* **29**: 1136-1145.

Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, and Sahi J (2012) A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. *J Pharm Sci* **101**: 3989-4002.

Tocco DJ, Duncan AE, deLuna FA, Smith JL, Walker RW, and Vandenneuvel WJ (1980) Timolol metabolism in man and laboratory animals. *Drug Metab Dispos* **8**: 236-240.

USFDA (2016) Guidance for Industry: Safety Testing of Drug Metabolites.

USFDA (2017) Guidance for Industry: In Vitro Metabolism and Transporter-Mediated Drug-Drug Interaction Studies.

Wang WW, Khetani SR, Krzyzewski S, Duignan DB, and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. *Drug Metab Dispos* **38**: 1900-1905.

DMD # 82867

Footnotes

Reprint requests to:

Dr. J. Matthew Hutzler

Q² Solutions, Bioanalytical and ADME Labs

5225 Exploration Drive, Indianapolis, IN 46241

Email: matt.hutzler@Q2LabSolutions.com

DMD # 82867

Legend for Figures

Figure 1. A) Extracted Ion Chromatograms (XICs) showing metabolite profile of timolol following incubations in human suspended hepatocytes (4 hours) and H μ REL model (up to 7 days). B) Proposed metabolic pathways of timolol. Metabolites highlighted in boxes are consistent with previously published human metabolite data. In vivo data was obtained from Tocco et al., 1980.

Figure 2. A) Extracted Ion Chromatograms (XICs) showing metabolite profile of meloxicam following incubations in human suspended hepatocytes (4 hours) and H μ REL model (up to 7 days). B) Proposed metabolic pathways of meloxicam. Metabolites highlighted in boxes are consistent with previously published human metabolite data. In vivo data was obtained from Schmid et al., 1995.

Figure 3. A) Extracted Ion Chromatograms (XICs) showing metabolite profile of linezolid following incubations in human suspended hepatocytes (4 hours) and H μ REL model (up to 7 days). B) Proposed metabolic pathways of linezolid. Metabolites highlighted in boxes are consistent with previously published human metabolite data. In vivo data was obtained from Slatter et al., 2001.

Figure 4. A) Extracted Ion Chromatograms (XICs) showing metabolite profile of XK469 following incubations in human suspended hepatocytes (4 hours) and H μ REL model (up to 7 days). B) Proposed metabolic pathways of XK469. Metabolites highlighted in boxes are consistent with previously published human metabolite data. In vivo data was obtained from Anderson et al., 2005.

DMD # 82867

Table 1. Summary of Metabolites Observed Following Incubation in Human Hepatocyte


Suspension and H μ REL Coculture Model and Comparison to Reported In Vivo Metabolite Data.

Compound	Metabolite	Observed <i>m/z</i>	Hepatocyte Suspension	H μ REL Coculture Model	Reported In Vivo*
Timolol	Parent Drug	317.1638	X	X	X
T1	Tim + Gluc	493.1955	-	X	
T2	Tim – C ₂ H ₂	291.1485	-	X	X
T3	Tim + 2O (a)	349.1536	-	X	X
T4	Tim + 2O (b)	349.1537	-	X	X
T5	Tim + O (a)	333.1592	X	X	X
T6	Tim + O (b)	333.1589	-	X	
Meloxicam	Parent Drug	352.0417	X	X	X
M1	Melox + O + Gluc	544.0679	-	X	
M2	Melox Cleavage	216.0323	-	Trace	X
M3	Melox + O	368.0368	-	Trace	
M4	Melox-COOH	382.0154	-	X	X
M5	Melox-OH	368.0362	Trace	X	X
M6	Melox + 4H + O	372.0676	-	X	
Linezolid	Parent Drug	338.1505	X	X	X
L1	Lin + 2O (a)	370.1403	Trace	X	X
L2	Lin + 2O (b)	370.1404	X	X	X
L3	Lin – C ₂ H ₂	312.1352	-	Trace	X
L4	Lin + H ₂ O (a)	356.1611	-	Trace	X
L5	Lin + H ₂ O (b)	356.1614	-	Trace	X
L6	Lin – C ₂ H ₂ O	296.1402	-	Trace	X
L7	Lin + 2O – C ₂ H ₄ O	326.1147	-	X	X
L8	Lin + O – 2H	352.1300	-	Trace	X
XK469	Parent Drug	345.0632	X	X	X
X1	XK469-Cys-2H (a)	464.0670	-	X	
X2	XK469-Cys-2H (b)	464.0668	-	X	
X3	XK469-AcetylCys-2H	506.0775	-	X	
X4	XK469-Taur	452.0668	-	X	X
X5	XK469-Gly	402.0844	-	X	X
X6	XK469-OH	361.0580	Trace	X	X
*X-Gluc	XK469-Gluc	521.0946	-	X	X

-, Not detected; * Multiple glucuronide conjugates were observed.



DMD # 82867

Figure 1.




DMD # 82867

Figure 2.




DMD # 82867

Figure 3.




DMD # 82867

Figure 4.



B



Drug Metabolism and Disposition

Assessment of the Biotransformation of Low Turnover Drugs in the H μ REL[®] Human

Hepatocyte Coculture Model

Richard Burton, Todd Hieronymus, Taysir Chamem, David Heim, Shelby Anderson, Xiaochun Zhu, and





J. Matthew Hutzler






Q² Solutions, a Quintiles Quest Joint Venture

Bioanalytical and ADME Labs






Indianapolis, IN 46241

Supplemental Table 1. Fragmentation of Parent Drug and Key Fragment Ions of Metabolites.







Compound/Metabolite	Metabolite	[M + H] ⁺ (<i>m/z</i>)	Fragment Ions (MS ²)
<p>Timolol</p>  <p><i>m/z</i> 113 ←</p> <p><i>m/z</i> 130 ←</p> <p><i>m/z</i> 188 (+H) ←</p> <p><i>m/z</i> 244 ←</p> <p><i>m/z</i> 261 (+H) ←</p> <p><i>m/z</i> 144 = <i>m/z</i> 188 - C₂H₄O</p> <p><i>m/z</i> 74 = <i>m/z</i> 130 - C₄H₈</p>	Parent Drug	317.1638	261, 244 , 243, 188, 144, 130, 113, 74
	T1 , Tim + Gluc	493.1955	437, 420, 401, 339, 317, 306, 303, 261, 244 , 243, 188, 186, 130, 74
	T2 , Tim - C ₂ H ₂	291.1485	235, 218, 217, 162 , 144, 130, 74
	T3 , Tim + 2O (a)	349.1536	293, 276, 275, 247, 220, 202, 176, 174 , 158, 144, 130, 86, 74

Compound/Metabolite	Metabolite	[M + H] ⁺ (<i>m/z</i>)	Fragment Ions (MS ²)
	T4 , Tim + 2O (b)	349.1537	293, 276, 275, 220, 202, 174, 144 , 130, 103, 74
	T5 , Tim + O (a)	333.1592	259, 242, 241, 198, 186 , 130, 74
	T6 , Tim + O (b)	333.1589	261, 244 , 243, 188, 146, 144, 113, 74
Meloxicam 	Parent Drug	352.0417	265, 210, 184, 141, 115 , 88
M1 , Melox + O + Gluc 	M1 , Melox + O + Gluc	544.0679	368, 342, 341, 203, 202, 141, 115







Compound/Metabolite	Metabolite	[M + H] ⁺	Fragment Ions
---------------------	------------	----------------------	---------------

		(<i>m/z</i>)	(<i>MS</i> ²)
	M2 , Melox Cleavage	216.0323	198 , 185, 121
	M3 , Melox + O	368.0368	141, 115
	M4 , Melox-COOH	382.0154	214, 171, 145 , 127, 101
	M5 , Melox-OH	368.0362	210, 200, 157, 139, 131 , 127, 113, 101
	M6 , Melox + 4H + O	372.0676	255, 238, 210, 135 , 118, 117, 76






Compound/Metabolite	Metabolite	[M + H] ⁺ (<i>m/z</i>)	Fragment Ions (<i>MS</i> ²)
---------------------	------------	----------------------------------------	---------------------------------------------

<p>Linezolid</p>  <p> $m/z\ 241\ (+2H)$ $m/z\ 235\ (-H)$ $m/z\ 296\ (+H)$ </p> <p> $m/z\ 294 = m/z\ 338 - CO_2$ $m/z\ 215 = m/z\ 235 - HF$ $m/z\ 209 = m/z\ 235 - C_2H_2$ $m/z\ 195 = m/z\ 241 - HCOOH$ $m/z\ 191 = m/z\ 235 - C_2H_4O$ $m/z\ 189 = m/z\ 235 - C_2H_6O$ </p>	Parent Drug	338.1505	296 , 294, 252, 241, 235, 215, 209, 195, 191, 189, 148
	L1 , Lin + 2O (a)	370.1403	328, 324 , 311, 310, 282, 267, 238, 221, 181, 177
	L2 , Lin + 2O (b)	370.1404	328 , 282, 273, 267, 252, 241, 227, 222, 197, 191, 165, 163, 151, 139, 137, 103
	L3 , Lin - C ₂ H ₂	312.1352	270 , 252, 225, 223, 215, 209, 197, 191, 183, 169, 164, 151, 139
	L4 , Lin + H ₂ O (a)	356.1611	338, 314, 311, 296, 294, 280, 270, 267 , 253, 235, 213, 208
	L5 , Lin + H ₂ O (b)	356.1614	314, 252 , 222, 200, 191

Compound/Metabolite	Metabolite	[M + H] ⁺ (<i>m/z</i>)	Fragment Ions (MS ²)
---------------------	------------	----------------------------------------	-------------------------------------

	L6 , Lin - C ₂ H ₂ O	296.1402	252, 209, 200, 195
	L7 , Lin + 2O - C ₂ H ₄ O	326.1147	284, 238 , 225, 223, 197, 183, 177, 164, 163, 151, 139
+ O - 2H 	L8 , Lin + O - 2H	352.1300	324 , 310, 282, 223
XK469 	Parent Drug	345.0632	299 , 273, 272, 271, 255, 244, 243, 181, 121, 91
Cys-2H 	X1 , XK469-Cys-2H (a)	464.0670	428, 382, 377, 375 , 356, 347, 331, 329, 275
Cys-2H 	X2 , XK469-Cys-2H (b)	464.0668	447 , 419, 401, 389, 375, 374, 356, 329, 301

Compound/Metabolite	Metabolite	[M + H] ⁺ (<i>m/z</i>)	Fragment Ions (MS ²)
	X3 , XK469-AcetylCys-	506.0775	447, 419, 418,

<p>AcetylCys-2H</p> 	2H		401, 377 , 331, 304, 305, 130
	X4, XK469-Taur	452.0668	327, 299 , 273, 272, 271, 243, 236, 152, 126
	X5, XK469-Gly	402.0844	327, 299 , 273, 272, 271, 243, 236, 207
	X6, XK469-OH	361.0580	315 , 297, 289, 288, 287, 271, 260, 259, 231, 224, 223, 121
	X-Gluc, XK469-Gluc	521.0946	345, 299 , 273, 272, 271